The FDA has placed a partial clinical hold on a Phase I study of Foghorn Therapeutics’ investigational protein degrader FHD-609 after a patient developed a grade 4 QTc prolongation event, the company announced Monday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,